Agur Provident & Training Funds Management LTD Gilead Sciences, Inc. Transaction History

Agur Provident & Training Funds Management LTD

$329 Million
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $1.22 Million - $1.37 Million	-19,509 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $1.41 Million - $1.67 Million	19,509	19,509 $1.38 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.1 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.07 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.71 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.56 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Agur Provident & Training Funds Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Agur Provident & Training Funds Management LTD with notifications on news.

Account